多替拉韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "多替拉韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

5nih.gov

4^th place

5^th place

3doi.org

2^nd place

23^rd place

3web.archive.org

1^st place

3medicinespatentpool.org

low place

3fda.gov

447^th place

581^st place

2drugs.com

399^th place

208^th place

2hiv.gov

low place

2healthpolicy-watch.news

low place

1tga.gov.au

3,984^th place

1,603^rd place

1canada.ca

1,712^th place

3,316^th place

1europa.eu

68^th place

209^th place

1handle.net

102^nd place

492^nd place

1semanticscholar.org

11^th place

332^nd place

1who.int

195^th place

179^th place

1reuters.com

49^th place

81^st place

1yahoo.com

38^th place

9^th place

1viivhealthcare.ca

low place

1gsk.com

low place

1statnews.com

8,771^st place

9,752^nd place

1unaids.org

5,436^th place

5,218^th place

1viivhealthcare.com

low place

1unitaid.org

low place

canada.ca

Drug and medical device highlights 2018: Helping you maintain and improve your health. Health Canada. 2020-10-14 [2024-04-17].

doi.org

Gill MM, Khumalo P, Chouraya C, Kunene M, Dlamini F, Hoffman HJ; et al. Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.. Open Forum Infect Dis. 2023, 10 (9): ofad441. PMC 10502921 . PMID 37720700. doi:10.1093/ofid/ofad441.
Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy. April 2020, 18 (4): 279–292. PMID 32067525. S2CID 211160876. doi:10.1080/14787210.2020.1729742.
Patel R, Evitt L, Mariolis I, Di Giambenedetto S, d'Arminio Monforte A, Casado J, et al. HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious Diseases and Therapy. August 2021, 10 (4): 2051–2070. PMC 8572911 . PMID 34426899. doi:10.1007/s40121-021-00522-7.

drugs.com

Dolutegravir (Tivicay) Use During Pregnancy. Drugs.com. 2018-10-16 [2020-02-13].
Dolutegravir Sodium Monograph for Professionals. Drugs.com. [2019-04-20] （英语）.

europa.eu

ema.europa.eu

Tivicay EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-02-13].

fda.gov

FDA approves new drug to treat HIV infection. Food and Drug Administration. 2013-08-12. （原始内容存档于2014-02-08）.
FDA Approves Drug to Treat Infants and Children with HIV. U.S. Food and Drug Administration (FDA) (新闻稿). 2020-06-12 [2020-06-12].

accessdata.fda.gov

Drug Approval Package: Tivicay (dolutegravir) Tablets NDA #204790. U.S. Food and Drug Administration (FDA). 2013-09-13 [2020-06-12].

gsk.com

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV. GSK (新闻稿). [2020-06-12].

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

healthpolicy-watch.news

Colombia Issues Compulsory License To Enable It To Access Generic HIV Drug, Dolutegravir - Health Policy Watch. 2024-04-25 [2024-07-28] （美国英语）.
Shetty, Disha. World’s Leading HIV Drug Reduces Carbon Emissions by 26 Million Tons In Comparison to Predecessor. Health Policy Watch. 2024-07-15.

hiv.gov

clinicalinfo.hiv.gov

What to Start: Initial Antiretroviral Regimens During Pregnancy for People Who Are Antiretroviral-Naïve. Clinicalinfo. 2024-01-31 [2024-07-15].
Case-Specific Use of Antiretroviral Drugs in Pregnant and Nonpregnant People Trying to Conceive. Clinicalinfo. [2024-07-15].

medicinespatentpool.org

More than 100 low- and middle-income countries have now received the WHO-recommended treatment for HIV thanks to access-oriented voluntary licensing agreements - MPP. [2024-07-28] （美国英语）.
DOLUTEGRAVIR - PAEDIATRICS (DTG) - MPP. [2024-07-28] （美国英语）.
Giten Khwairakpam. Thailand’s switch to dolutegravir: more generic versions needed!. medicines patent pool. 2021-10-29 [2024-10-11].

nih.gov

ncbi.nlm.nih.gov

Gill MM, Khumalo P, Chouraya C, Kunene M, Dlamini F, Hoffman HJ; et al. Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.. Open Forum Infect Dis. 2023, 10 (9): ofad441. PMC 10502921 . PMID 37720700. doi:10.1093/ofid/ofad441.
Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy. April 2020, 18 (4): 279–292. PMID 32067525. S2CID 211160876. doi:10.1080/14787210.2020.1729742.
Patel R, Evitt L, Mariolis I, Di Giambenedetto S, d'Arminio Monforte A, Casado J, et al. HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious Diseases and Therapy. August 2021, 10 (4): 2051–2070. PMC 8572911 . PMID 34426899. doi:10.1007/s40121-021-00522-7.
Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. World Health Organization. 2020-10-29 [2024-07-15].

dailymed.nlm.nih.gov

Tivicay- dolutegravir sodium tablet, film coated. DailyMed. 2019-10-24 [2020-02-13].

reuters.com

U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay. Reuters. 2013-08-12 [2020-02-13].

semanticscholar.org

api.semanticscholar.org

Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy. April 2020, 18 (4): 279–292. PMID 32067525. S2CID 211160876. doi:10.1080/14787210.2020.1729742.